KDR and non-small cell lung carcinoma: However, most small-molecule vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs) including sunitinib, sorafenib, and pazopanib have low selectivity.[1] Anlotinib (AL3818) is a multitarget TKI,[1] which has been approved as third-line treatment for refractory non-small cell lung cancer (NSCLC) in China since May 2018.